Page last updated: 2024-11-08

secalonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

secalonic acid: consists of 4 acids (A,C,D,E) differing only in their stereochemistry; RN given is for parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID423972
CHEMBL ID30050
MeSH IDM0053735

Synonyms (31)

Synonym
NSC159631 ,
nsc-268921
[7,4'a-dicarboxylic acid, 2,2',3,3',4,4',9,9'-octahydro-1,1',4,4',8,8'-hexahydroxy-3,3'-dimethyl-9,9'-dioxo-, dimethyl ester, [3s-[3.alpha.,4.beta.,4a.beta.,7(3'r*,4's*,4'as*)]]-
secalonsaure d
nsc268920
(7,4'a-dicarboxylic acid, 2,2',3,3',4,4',9,9'-octahydro-1,1',4,4',8,8'-hexahydroxy-3,3'-dimethyl-9,9'-dioxo-, dimethyl ester, [3s-[3.alpha.,4.beta.,4a.beta.,7(3'r*,4's*,4'as*)]]-
SAD ,
(7,4'a-dicarboxylic acid, 2,2',3,3',4,4',9,9'-octahydro-1,1',4,4',8,8'-hexahydroxy-3,3'-dimethyl-9,9'-dioxo-, dimethyl ester, [3s-[3-.alpha.,4-.beta.,4a-.beta.,7(3'r,4's,4'as)]]
secalonsaure b
nsc268921
ergochrome aa (2,6-.alpha.,10-.beta.-5',6'-.alpha.,10'-.beta.
secalonsaure a
35287-69-5
nsc-268922
nsc-268920
nsc268922
CHEMBL30050
secalonic acid
56283-72-8
(7,7'-bi-4ah-xanthene)-4a,4'a-dicarboxylic acid, 2,2',3,3',4,4',9,9'-octahydro-1,1',4,4',8,8'-hexahydroxy-3,3'-dimethyl-9,9'-dioxo-, dimethyl ester, (3s-(3-.alpha.,4-.beta.,4a-.beta.,7(3'r,4's,4'as)))
ergochrome aa (2,2')-5-.beta.,6-.alpha.,10-.beta.-5',6'-.alpha.,10'-.beta.
ergochrome aa(2,2'), (5.beta.,6.alpha.,10.beta.)-(5'.beta.,6'.alpha.,10'.beta.)-
[7,7'-bi-4ah-xanthene]-4a,4'a-dicarboxylic acid, 2,2',3,3',4,4',9,9'-octahydro-1,1',4,4',8,8'-hexahydroxy-3,3'-dimethyl-9,9'-dioxo-, dimethyl ester, [3s-[3.alpha.,4.beta.,4a.beta.,7(3'r*,4's*,4'as*)]]-
DRYDKQOPVBDZMQ-UHFFFAOYSA-N
methyl(3s,4r,4ar)-7-[(5r,6s,10ar)-1,5,9-trihydroxy-10a-methoxycarbonyl-6-methyl-8-oxo-6,7-dihydro-5h-xanthen-2-yl]-4,8,9-trihydroxy-3-methyl-1-oxo-3,4-dihydro-2h-xanthene-4a-carboxylate
dimethyl 1,1',5,5',9,9'-hexahydroxy-6,6'-dimethyl-8,8'-dioxo-5,5',6,6',7,7',8,8'-octahydro-10ah,10a'h-2,2'-bixanthene-10a,10a'-dicarboxylate
secalonic acid d from penicillium*oxalicum
DTXSID001017604
dimethyl 1,1',5,5',8,8'-hexahydroxy-6,6'-dimethyl-9,9'-dioxo-5,5',6,6',7,7',9,9'-octahydro-10ah,10'ah-[2,2'-bixanthene]-10a,10'a-dicarboxylate
DTXSID50956725
(3s,3's,4s,4'r,4ar,4'ar)-2,2',3,3',4,4',9,9'-octahydro-1,1',4,4',8,8'-hexahydroxy-3,3'-dimethyl-9,9'-dioxo-7,7'-bi(4ah-xanthene)-4a,4'a-dicarboxylic acid dimethyl ester

Research Excerpts

Overview

Secalonic acid D (SAD) is an acutely toxic and teratogenic fungal metabolite produced by Penicillium oxalium in corn. It causes cleft palate in the offspring of treated pregnant mice.

ExcerptReferenceRelevance
"Secalonic acid A (SAA) is a natural compound found in marine fungi. "( Secalonic acid A protects dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP⁺)-induced cell death via the mitochondrial apoptotic pathway.
Chen, R; Wang, H; Wang, X; Zhai, A; Zhu, X, 2013
)
3.28
"Secalonic acid-D (SAD) is a teratogenic mycotoxin inducing cleft palate (CP) in the offspring of the exposed mice by reducing palatal shelf size secondary to reduced proliferation of the palatal mesenchymal (PM) cells. "( Relevance of the palatal protein kinase A pathway to the pathogenesis of cleft palate by secalonic acid D in mice.
Balasubramanian, G; Dhulipala, VC; Hanumegowda, UM; Reddy, CS, 2004
)
1.99
"Secalonic acid D (SAD) is an acutely toxic and teratogenic fungal metabolite produced by Penicillium oxalium in corn and other cereal grains. "( Interaction of secalonic acid D with phenobarbital, 3-methyl cholanthrene, and SKF-525A in mice.
Hayes, AW; Reddy, CS; Reddy, RV,
)
1.93
"Secalonic acid D is an acutely toxic and teratogenic mycotoxin, produced by Penicillium oxalicum in corn. "( Mutagenicity of secalonic acid D in mice.
Chan, PK; Hayes, AW; Reddy, CS; Reddy, RV, 1980
)
2.05
"Secalonic acid D (SAD) is an acutely toxic, teratogenic and possibly mutagenic fungal metabolite produced in corn by Penicillium oxalicum. "( High-performance liquid chromatographic analysis of the mycotoxin secalonic acid D and its application to biological fluids.
Hayes, AW; Reddy, CS; Reddy, RV, 1981
)
1.94
"Secalonic acid D (SAD) is a teratogenic mycotoxin that causes cleft palate in the offspring of treated pregnant mice. "( Role of maternal plasma corticosterone elevation in the teratogenicity of secalonic acid D in mice.
Eldeib, MM; Reddy, CS, 1990
)
1.95

Effects

ExcerptReferenceRelevance
"Secalonic acid F (SAF) has been previously identified, however, little is known about its cytotoxic activity and related cytotoxic mechanism. "( Differential proteomic analysis of HL60 cells treated with secalonic acid F reveals caspase 3-induced cleavage of Rho GDP dissociation inhibitor 2.
Li, N; Qiu, Y; Tang, X; Wang, Y; Wu, Z; Yi, Z; Zhang, Q; Zhong, T, 2012
)
1.82

Toxicity

ExcerptReferenceRelevance
" The ip LD50 values of 37, 31, and 27 mg/kg were obtained for Charles River CD-1, Texas (ICR), and Sprague-Dawley (CF-1) strains of mice, respectively."( Toxicity of Secalonic acid D.
Ciegler, A; Hayes, AW; Reddy, CS; Williams, WL, 1979
)
0.64
" Body weights, toxic signs, and mortality were used to arrive at no observable effect level (NOEL)."( Neurotoxic effects of secalonic acid D in mice during subchronic postnatal exposure.
Montella, PG; Reddy, CS, 1991
)
0.6
" Dose response was studied by intragastric and intratracheal instillation, and SAD was given in suspension in Krebs-Ringer phosphate solution at doses well below the reported LD50 values for both rats and mice."( Secalonic acid D toxicity in rat lung.
Ciegler, A; Green, FH; Sorenson, WG; Vallyathan, V, 1982
)
1.71

Dosage Studied

ExcerptRelevanceReference
"To establish a dose-response of neurotoxic effects to daily oral doses of the mycotoxin secalonic acid D (SAD), as well as to correlate the neonatal behavioral responses to smaller doses of SAD with the attendant neurochemical effects in mice, 5 neonates of each sex were placed with each mother and 4 litters were treated orally with 0 to 5 mg/kg of SAD daily from postnatal day (PND) 3 through 35."( Neurotoxic effects of secalonic acid D in mice during subchronic postnatal exposure.
Montella, PG; Reddy, CS, 1991
)
0.82
"01) elevations in plasma corticosterone concentrations were seen 24 and 48 hr following dosing of SAD in NaHCO3 with concentrations reaching a peak just prior to the onset of shelf elevation and fusion."( Role of maternal plasma corticosterone elevation in the teratogenicity of secalonic acid D in mice.
Eldeib, MM; Reddy, CS, 1990
)
0.51
" A significant dose-response effect in olfactory discrimination existed between the groups exposed to postnatal SAD."( Behavioral and developmental effects in suckling mice following maternal exposure to the mycotoxin secalonic acid D.
Bolon, B; St Omer, VE, 1989
)
0.49
" In experimental mouse models of breast cancer, SAD dosing produced no apparent toxicities (either orally or intraperitoneal) at levels that yielded antitumor effects."( Secalonic Acid-D Represses HIF1α/VEGF-Mediated Angiogenesis by Regulating the Akt/mTOR/p70S6K Signaling Cascade.
Bhushan, S; Chandan, BK; Faruk, A; Guru, SK; Jaglan, S; Kumar, A; Kumar, M; Kumar, S; Lattoo, SK; Malik, F; Pathania, AS; Ramesh, D; Rana, S; Saxena, AK; Shah, BA; Sharma, JP; Sharma, PR; Tasduq, SA; Vishwakarma, RA, 2015
)
1.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID69132Inhibitory activity against tetracycline uptake in everted membrane vesicles derived from Tc-resistant Escherichia coli bearing class B tetracycline resistance efflux protein (Tet)1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (29.58)18.7374
1990's8 (11.27)18.2507
2000's18 (25.35)29.6817
2010's17 (23.94)24.3611
2020's7 (9.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.05 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (6.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other73 (93.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]